Celtek Bioscience explains biotechnology through mechanisms, experimental methods, and careful interpretation. Our central standard is simple: a conclusion should not extend beyond what the cited source or experiment can establish. We identify the evidence behind important claims, consider its currency and limitations, and distinguish direct findings from reasonable interpretation.
How we evaluate different types of evidence
Published specifications establish what a manufacturer, service provider, or technical document reports under stated conditions. They can clarify design, composition, or intended capability, but they do not automatically demonstrate performance in every experimental system. Time-sensitive details—including services, program status, and technical capabilities—require current first-party documentation.
Scientific research is assessed according to study design and proximity to the question. Original peer-reviewed studies and methods papers are preferred for experimental findings. Primary databases, trial records, patents, grant records, and regulatory documents are used when appropriate. Strong reviews can provide context, but important claims are traced to primary evidence when practical.
Professional and regulatory guidance can establish accepted terminology, reporting expectations, or recommended practices. Its relevance depends on the issuing organization, publication date, jurisdiction, and scope. Guidance is not treated as experimental proof of a specific biological effect.
Documented direct testing is described only when records establish what was tested, how it was tested, and what was observed. A testing claim should identify the method, conditions, controls, and relevant limitations. We do not present literature analysis, company specifications, or general scientific reasoning as first-hand laboratory testing.
Matching conclusions to the experiment
The more important distinction is often between what an assay measures and what a reader might infer from it. Binding does not establish cellular uptake. Uptake does not establish cytosolic delivery, target engagement, or a functional effect. Likewise, a cell-based result does not demonstrate performance in an animal, and an animal-model result does not establish clinical effectiveness in humans.
We therefore consider the biological model, controls, detection method, endpoint, exposure conditions, and potential artifacts. Where multiple methods answer different parts of a question, those methods are kept separate. For example, chromatographic purity is not molecular identity, transcript abundance is not protein activity, and biodistribution is not interchangeable with pharmacokinetics. Our guide to how evidence changes from cell culture to human trials illustrates this evidence ladder, while cell-surface binding versus true internalization shows how assay design can change the interpretation of delivery data.
Currency, conflicts, and historical claims
Current project-specific documentation takes priority for claims about an active program or capability. For scientific findings, we favor underlying publications and primary records. Current company pages can establish what an organization presently reports, while archived material is evidence of what was stated at a particular time—not automatic proof of current status.
When credible sources conflict, we compare their dates, methods, definitions, and directness. Material uncertainty is stated clearly; if a claim cannot be supported with suitable evidence, it is qualified or omitted. Historical programs are presented with dates and source context so that earlier research is not confused with present activity.
Corrections and further information
These standards complement our Editorial Policy and Trust & Transparency pages. To report a factual error, outdated source, or unclear interpretation, contact admin@celtek-bioscience.com with the page title and supporting information.